This research article from the European Journal of Neurology presents the results of the ADVANCE-CIDP IVIG trial, which investigated the effectiveness and safety of intravenous immunoglobulin 10% therapy (GAMMAGARD LIQUID/Kiovig) for treating relapses in adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). The study found that IVIG 10% was effective in treating CIDP relapses and improving functional abilities, with a high responder rate and a favorable safety profile in patients who had relapsed during a previous trial of subcutaneous immunoglobulin or placebo. These findings support the use of IVIG 10% as a rescue therapy for CIDP relapse, and contributed to its recent approval in the United States for this purpose.

Multifocal Motor Neuropathy - A Comprehensive Review

Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder — recommendations from ECTRIMS and the EBMT

Cardioprotective Glucose-Lowering Agents and Dementia Risk

A Systematic Review and Meta-Analysis

There are four serum NFL laboratory assays. Which one is the most accurate diagnostic and prognostic marker for ALS?

There is a link between stress and cryptogenic stroke in young adults.

How can AI be used as an observation tool for diagnosis in Neurology.

Joint EANM/EANO/RANO/SNMMI practice guideline/procedure standard for PET imaging of brain metastases

Pyridostigmine in the management of orthostatic hypotension: a systematic review and meta-analysis

Montreal Cognitive Assessment vs the Mini-Mental State Examination as a Screening Tool for Patients With Genetic Frontotemporal Dementia